Dimensional Fund Advisors
TAK icon

Dimensional Fund Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Dimensional Fund Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53M Buy
157,965
+22,286
+16% +$369K ﹤0.01% 2692
2026
Q1 		$2.51M Sell
135,679
-27,607
-17% -$485K ﹤0.01% 2655
2025
Q4 		$2.55M Sell
163,286
-5,270
-3% -$75.3K ﹤0.01% 2684
2025
Q3 		$2.47M Buy
168,556
+8,840
+6% +$131K ﹤0.01% 2717
2025
Q2 		$2.47M Sell
159,716
-17,290
-10% -$255K ﹤0.01% 2711
2025
Q1 		$2.63M Sell
177,006
-4,923
-3% -$69K ﹤0.01% 2660
2024
Q4 		$2.41M Buy
181,929
+68,200
+60% +$937K ﹤0.01% 2742
2024
Q3 		$1.62M Sell
113,729
-525
-0.5% -$7.45K ﹤0.01% 2827
2024
Q2 		$1.48M Buy
114,254
+15,075
+15% +$200K ﹤0.01% 2832
2024
Q1 		$1.38M Buy
99,179
+7,171
+8% +$104K ﹤0.01% 2866
2023
Q4 		$1.31M Sell
92,008
-42,367
-32% -$601K ﹤0.01% 2879
2023
Q3 		$2.08M Buy
134,375
+1,353
+1% +$20.9K ﹤0.01% 2771
2023
Q2 		$2.09M Sell
133,022
-10,093
-7% -$165K ﹤0.01% 2773
2023
Q1 		$2.36M Buy
+143,115
New +$2.28M ﹤0.01% 2707
2022
Q3 		$1.72M Buy
132,632
+10,713
+9% +$149K ﹤0.01% 2757
2022
Q2 		$1.71M Buy
121,919
+15,157
+14% +$216K ﹤0.01% 2789
2022
Q1 		$1.53M Sell
106,762
-10,687
-9% -$157K ﹤0.01% 2890
2021
Q4 		$1.6M Buy
117,449
+31,920
+37% +$448K ﹤0.01% 2905
2021
Q3 		$1.4M Hold
85,529
– – ﹤0.01% 2953
2021
Q2 		$1.44M Sell
85,529
-5,060
-6% -$86.1K ﹤0.01% 2954
2021
Q1 		$1.65M Hold
90,589
– – ﹤0.01% 2901
2020
Q4 		$1.65M Buy
90,589
+25,085
+38% +$440K ﹤0.01% 2859
2020
Q3 		$1.17M Sell
65,504
-68,861
-51% -$1.25M ﹤0.01% 2894
2020
Q2 		$2.41M Sell
134,365
-119,647
-47% -$2.15M ﹤0.01% 2704
2020
Q1 		$3.86M Sell
254,012
-43,789
-15% -$794K ﹤0.01% 2507
2019
Q4 		$5.88M Sell
297,801
-386,686
-56% -$7.4M ﹤0.01% 2555
2019
Q3 		$11.8M Sell
684,487
-119,559
-15% -$2.07M ﹤0.01% 2279
2019
Q2 		$14.2M Sell
804,046
-464,821
-37% -$8.46M 0.01% 2231
2019
Q1 		$26M Buy
+1,268,867
New +$25.5M 0.01% 1909

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Dimensional Fund Advisors's TAK Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Takeda Pharmaceutical (TAK) stake by 16% in Q2 2026, buying an estimated $369K and bringing the position to 157,965 shares worth $2.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2692.

Dimensional Fund Advisors first reported a position in TAK in Q1 2019 and has held it in 29 quarters since. The position peaked at $26M in Q1 2019. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Dimensional Fund Advisors held 157,965 shares of Takeda Pharmaceutical worth $2.53M as of Q2 2026.
  • Dimensional Fund Advisors bought 22,286 Takeda Pharmaceutical shares in Q2 2026, an estimated $369K.
  • Takeda Pharmaceutical made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2692 holding.
  • Dimensional Fund Advisors first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 29 quarters since.
  • Dimensional Fund Advisors's Takeda Pharmaceutical position peaked at $26M in Q1 2019.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.